
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.7 | -8.52618757613 | 8.21 | 8.21 | 7.335 | 1168316 | 7.75996533 | CS |
4 | -0.2 | -2.59403372244 | 7.71 | 9.16 | 7.335 | 1757943 | 8.45567871 | CS |
12 | -3.255 | -30.2368787738 | 10.765 | 11.11 | 6.98 | 1707007 | 8.5120581 | CS |
26 | -13.49 | -64.2380952381 | 21 | 21.569 | 6.98 | 1409749 | 11.0341798 | CS |
52 | -14.14 | -65.311778291 | 21.65 | 24.17 | 6.98 | 1080333 | 14.48987853 | CS |
156 | -8.78 | -53.898096992 | 16.29 | 24.17 | 6.98 | 945217 | 14.10055286 | CS |
260 | -5.41 | -41.8730650155 | 12.92 | 43 | 6.34 | 847643 | 16.9139406 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions